The tumors responded to the anti-PD-1 Ab + entinostat + celecoxib regimen remarkably well (Fig. 1A), eradicating primary tumors in 4 out of 7 mice, with 85% survival at day 53 after tumor implantation (Fig. 1B–D). The gene discussed is PDCD1; the disease is neoplasm.